View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
This trial is available at multiple Sutter Locations. Please contact one of the following about Study SWOG S1900E
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky email@example.com
PAMF/Fremont: Tanya Pozniansky firstname.lastname@example.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Modesto: Stephanie Edmondson email@example.com
Solano-Vallejo Cancer Center: Stephanie Gonzales firstname.lastname@example.org
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org
Investigator: Tze-Ming Chen, M.D., FCCP
Investigator: Jiang Li, Ph.D., MPH